Search Results
Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Hans-Peter Holthoff in
Google Scholar
PubMed
Search for other papers by Julia Fassbender in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Search for other papers by Martin Ungerer in
Google Scholar
PubMed
mice were also studied. Free Thyroxine Levels and Thyrotropin Receptor Antibodies Serum fT4 and TSHR-binding inhibiting autoantibodies (TBII) levels were measured with Immulite 2000 XPi (Siemens, Erlangen, Germany) according to the
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Lars Folkestad in
Google Scholar
PubMed
Search for other papers by Frans Brandt in
Google Scholar
PubMed
Search for other papers by Thomas Brix in
Google Scholar
PubMed
Search for other papers by Marianne Vogsen in
Google Scholar
PubMed
Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Search for other papers by Peter Grupe in
Google Scholar
PubMed
Search for other papers by Jeanette Krogh Petersen in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
What Is Known about This Topic? The prevalence of thyrotoxicosis in patients with thyroid cancer is unknown. In view of the sparse reports, it is most likely very low. Thyrotropin receptor antibodies are seldom measured or found in
Search for other papers by Solène Castellnou in
Google Scholar
PubMed
Search for other papers by Patricia Bretones in
Google Scholar
PubMed
Search for other papers by Juliette Abeillon in
Google Scholar
PubMed
Search for other papers by Myriam Moret in
Google Scholar
PubMed
Search for other papers by Pauline Perrin in
Google Scholar
PubMed
Search for other papers by Karim Chikh in
Google Scholar
PubMed
Search for other papers by Véronique Raverot in
Google Scholar
PubMed
-9972 2 Diana T , Olivo PD , Kahaly GJ . Thyrotropin Receptor Blocking Antibodies . Horm Metab Res . 2018 Dec ; 50 ( 12 ): 853 – 62 . 10.1055/a-0723-9023 30286485 0018-5043 3 Kanike N , Davis A , Shekhawat PS
Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany
Search for other papers by Alan Chun Hong Lee in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
treatments for GH. CD40L, CD40 ligand; GH, Graves’ hyperthyroidism; MAb, monoclonal antibody; MHC Class II, major histocompatibility complex class II molecule; TSH-R, thyrotropin receptor; TSI, thyroid-stimulating immunoglobulin. Summary of Clinical
Search for other papers by Gerd Krause in
Google Scholar
PubMed
Search for other papers by Anja Eckstein in
Google Scholar
PubMed
Search for other papers by Ralf Schülein in
Google Scholar
PubMed
Introduction TSH-Receptor, Graves’ Disease and Graves’ Orbitopathy The thyrotropin receptor or thyroid-stimulating hormone (TSH) receptor (TSHR) is mainly expressed in follicular epithelial cells of the thyroid gland [ 1 ]. TSHR activation
Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Paul D. Olivo in
Google Scholar
PubMed
Search for other papers by Yie-Hwa Chang in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Introduction Autoantibodies against the thyrotropin receptor (TSH-R-Ab) play an important role in the pathogenesis of autoimmune thyroid diseases [ 1 - 5 ]. These functional antibodies demonstrate different effects on the TSH-R and can either
Search for other papers by John H. Lazarus in
Google Scholar
PubMed
features of Graves’ disease in the first trimester of pregnancy may occur due to stimulation of the thyroid both by human chorionic gonadotropin and thyrotropin receptor-stimulating antibodies [ 3 , 4 , 5 ]. The markedly increased thyroid hormone
Search for other papers by Ringo Manta in
Google Scholar
PubMed
Search for other papers by Charlotte Martin in
Google Scholar
PubMed
Search for other papers by Vinciane Muls in
Google Scholar
PubMed
Search for other papers by Kris G Poppe in
Google Scholar
PubMed
vedolizumab, oral budesonide and mycophenolic acid. In April 2020, the patient presented a mild COVID-19 and received hydroxychloroquine. Concomitantly, he developed transient hypothyroidism with negative thyroid peroxidase antibody (TPOAb) and thyrotropin-receptor
Search for other papers by Earn H. Gan in
Google Scholar
PubMed
Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed
Search for other papers by Ruth Plummer in
Google Scholar
PubMed
Search for other papers by Simon Pearce in
Google Scholar
PubMed
Search for other papers by Petros Perros in
Google Scholar
PubMed
.5–21.5). Thyroid peroxidase antibodies were elevated at >600 kU/L (reference range 0–34), as was the thyrotropin receptor antibody level, measured at 5.0 IU/L (reference range1.0–1.8; BRAHMS Kryptor TRAK assay), consistent with Graves disease (Fig. 1 ). The
Search for other papers by Joanna Bogusławska in
Google Scholar
PubMed
Search for other papers by Marlena Godlewska in
Google Scholar
PubMed
Search for other papers by Ewa Gajda in
Google Scholar
PubMed
Search for other papers by Agnieszka Piekiełko-Witkowska in
Google Scholar
PubMed
hypothyroidism. In contrast, GD is mainly associated with hyperthyroidism, resulting from the presence of thyroid-stimulating antibodies which activate thyrotropin receptor (TSHR) on thyrocytes, leading to thyroid hyperplasia. Only a minor number of GD patients
